Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference

Company Overview - Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for rare diseases affecting bone health and blood vessel function [3] - The company targets the PPi-Adenosine Pathway, which is crucial for bone health and vascular function, with disruptions in this pathway leading to severe diseases such as ENPP1 Deficiency [3] Key Developments - Doug Treco, Ph.D., CEO and Chairman of Inozyme, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, from 2:15-2:55pm ET [1] - A live webcast of the fireside chat will be available on Inozyme's website, along with a replay for a limited time [2] Product Pipeline - The lead investigational therapy, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy (ERT) aimed at restoring PPi and adenosine levels [3] - INZ-701 is currently in late-stage clinical development for ENPP1 Deficiency, with potential expansion into other indications related to deficiencies in the PPi-Adenosine Pathway [3]